Theolytics Showcases THEO-260 In Ovarian Cancer Trial At ESMO
13 Oct 2025 //
GLOBENEWSWIRE
Theolytics Names Matilde Saggese, MD, Chief Medical Officer
07 Oct 2025 //
GLOBENEWSWIRE
Theolytics Appoints David Apelian MD, PhD, MBA as CEO
17 Dec 2024 //
GLOBENEWSWIRE
Theolytics Doses 1st Patient in Ph I/IIa of THEO-260 in Cancer
19 Nov 2024 //
GLOBENEWSWIRE
Theolytics Awarded Significant £2M for Cancer Therapeutics Grant from UK
02 Sep 2024 //
GLOBENEWSWIRE
Theolytics successfully closes latest financing raising total of £19M
17 Apr 2024 //
GLOBENEWSWIRE

Market Place
Sourcing Support